Loading…
Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin
•Isoniazid and rifampicin are the most important first-line TB drugs.•Despite the drugs’ anti-mycobacterial properties, it can cause severe side effects.•Drug toxicity is a major contributor to TB treatment failure.•Metabolomics can be used to elucidate TB drug toxicity mechanisms.•Metabolomics can...
Saved in:
Published in: | Toxicology letters 2020-04, Vol.322, p.104-110 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c413t-121bdfb6618cee988cd367f613fdd5e0e3dfb088da6f2cb1ce877fe8950db0fe3 |
---|---|
cites | cdi_FETCH-LOGICAL-c413t-121bdfb6618cee988cd367f613fdd5e0e3dfb088da6f2cb1ce877fe8950db0fe3 |
container_end_page | 110 |
container_issue | |
container_start_page | 104 |
container_title | Toxicology letters |
container_volume | 322 |
creator | Combrink, Monique Loots, Du Toit du Preez, Ilse |
description | •Isoniazid and rifampicin are the most important first-line TB drugs.•Despite the drugs’ anti-mycobacterial properties, it can cause severe side effects.•Drug toxicity is a major contributor to TB treatment failure.•Metabolomics can be used to elucidate TB drug toxicity mechanisms.•Metabolomics can contribute to the development of less toxic TB drugs.
Isoniazid and rifampicin are well-known anti-mycobacterial agents and are widely used to treat pulmonary tuberculosis (TB) as part of the combined therapy approach, recommended by the World Health Organization. The ingestion of these first-line TB drugs are, however, not free of side effects, and are toxic to the liver, kidney, and central nervous system. These side effects are associated with poor treatment compliance, resulting in TB treatment failure, relapse and drug resistant TB. This occurrence has subsequently led to the recent application of novel research technologies, towards a better understanding of the underlying toxicity mechanisms of TB drugs in humans, mostly focussing on the 2 most important TB drugs: isoniazid and rifampicin. In this review, we discuss the contribution that one such an approach, termed metabolomics has made toward this field, and also highlight the impact that this might have towards the development of improved TB treatment regimens. |
doi_str_mv | 10.1016/j.toxlet.2020.01.018 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2345507981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378427420300266</els_id><sourcerecordid>2345507981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-121bdfb6618cee988cd367f613fdd5e0e3dfb088da6f2cb1ce877fe8950db0fe3</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMozvj4ByJZuumYNG2abgQRX6C40YWrkCY3mLFNxqSjjr_eyIwuhQt3cb9zD-cgdETJjBLKT-ezMXz2MM5KUpIZoXnEFppS0bQFo7zdRlPCGlFUZVNN0F5Kc0IIr3i9iyaMtoJy0UzR8z2Mqgt9GJxO2EDS0XWQ8CLCuwvL1K_w0r_68OFxtnPajSs8gH5R3qUh4WCxS8E79eUMVt7g6KwaFpnzB2jHqj7B4Wbvo6ery8eLm-Lu4fr24vyu0BVlY0FL2hnbcU6FBmiF0IbxxnLKrDE1EGD5SoQwittSd1SDaBoLoq2J6YgFto9O1n8XMbwtIY1ycElD3ysPOYAsWVXXpMmBM1qtUR1DShGsXEQ3qLiSlMifUuVcrkuVP6VKQvOILDveOCy7Acyf6LfFDJytAcg53x1EmbQDr8G4CHqUJrj_Hb4Bc4aN2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2345507981</pqid></control><display><type>article</type><title>Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Combrink, Monique ; Loots, Du Toit ; du Preez, Ilse</creator><creatorcontrib>Combrink, Monique ; Loots, Du Toit ; du Preez, Ilse</creatorcontrib><description>•Isoniazid and rifampicin are the most important first-line TB drugs.•Despite the drugs’ anti-mycobacterial properties, it can cause severe side effects.•Drug toxicity is a major contributor to TB treatment failure.•Metabolomics can be used to elucidate TB drug toxicity mechanisms.•Metabolomics can contribute to the development of less toxic TB drugs.
Isoniazid and rifampicin are well-known anti-mycobacterial agents and are widely used to treat pulmonary tuberculosis (TB) as part of the combined therapy approach, recommended by the World Health Organization. The ingestion of these first-line TB drugs are, however, not free of side effects, and are toxic to the liver, kidney, and central nervous system. These side effects are associated with poor treatment compliance, resulting in TB treatment failure, relapse and drug resistant TB. This occurrence has subsequently led to the recent application of novel research technologies, towards a better understanding of the underlying toxicity mechanisms of TB drugs in humans, mostly focussing on the 2 most important TB drugs: isoniazid and rifampicin. In this review, we discuss the contribution that one such an approach, termed metabolomics has made toward this field, and also highlight the impact that this might have towards the development of improved TB treatment regimens.</description><identifier>ISSN: 0378-4274</identifier><identifier>EISSN: 1879-3169</identifier><identifier>DOI: 10.1016/j.toxlet.2020.01.018</identifier><identifier>PMID: 31981687</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antitubercular Agents - metabolism ; Antitubercular Agents - toxicity ; Biomarkers - metabolism ; Biotransformation ; Drug-Related Side Effects and Adverse Reactions - diagnosis ; Drug-Related Side Effects and Adverse Reactions - etiology ; Drug-Related Side Effects and Adverse Reactions - metabolism ; Humans ; Isoniazid ; Isoniazid - metabolism ; Isoniazid - toxicity ; Metabolomics ; Metabolomics - methods ; Rifampicin ; Rifampin - metabolism ; Rifampin - toxicity ; Risk Assessment ; Toxicity ; Toxicity Tests - methods ; Tuberculosis</subject><ispartof>Toxicology letters, 2020-04, Vol.322, p.104-110</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-121bdfb6618cee988cd367f613fdd5e0e3dfb088da6f2cb1ce877fe8950db0fe3</citedby><cites>FETCH-LOGICAL-c413t-121bdfb6618cee988cd367f613fdd5e0e3dfb088da6f2cb1ce877fe8950db0fe3</cites><orcidid>0000-0002-5202-9097</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31981687$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Combrink, Monique</creatorcontrib><creatorcontrib>Loots, Du Toit</creatorcontrib><creatorcontrib>du Preez, Ilse</creatorcontrib><title>Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin</title><title>Toxicology letters</title><addtitle>Toxicol Lett</addtitle><description>•Isoniazid and rifampicin are the most important first-line TB drugs.•Despite the drugs’ anti-mycobacterial properties, it can cause severe side effects.•Drug toxicity is a major contributor to TB treatment failure.•Metabolomics can be used to elucidate TB drug toxicity mechanisms.•Metabolomics can contribute to the development of less toxic TB drugs.
Isoniazid and rifampicin are well-known anti-mycobacterial agents and are widely used to treat pulmonary tuberculosis (TB) as part of the combined therapy approach, recommended by the World Health Organization. The ingestion of these first-line TB drugs are, however, not free of side effects, and are toxic to the liver, kidney, and central nervous system. These side effects are associated with poor treatment compliance, resulting in TB treatment failure, relapse and drug resistant TB. This occurrence has subsequently led to the recent application of novel research technologies, towards a better understanding of the underlying toxicity mechanisms of TB drugs in humans, mostly focussing on the 2 most important TB drugs: isoniazid and rifampicin. In this review, we discuss the contribution that one such an approach, termed metabolomics has made toward this field, and also highlight the impact that this might have towards the development of improved TB treatment regimens.</description><subject>Animals</subject><subject>Antitubercular Agents - metabolism</subject><subject>Antitubercular Agents - toxicity</subject><subject>Biomarkers - metabolism</subject><subject>Biotransformation</subject><subject>Drug-Related Side Effects and Adverse Reactions - diagnosis</subject><subject>Drug-Related Side Effects and Adverse Reactions - etiology</subject><subject>Drug-Related Side Effects and Adverse Reactions - metabolism</subject><subject>Humans</subject><subject>Isoniazid</subject><subject>Isoniazid - metabolism</subject><subject>Isoniazid - toxicity</subject><subject>Metabolomics</subject><subject>Metabolomics - methods</subject><subject>Rifampicin</subject><subject>Rifampin - metabolism</subject><subject>Rifampin - toxicity</subject><subject>Risk Assessment</subject><subject>Toxicity</subject><subject>Toxicity Tests - methods</subject><subject>Tuberculosis</subject><issn>0378-4274</issn><issn>1879-3169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAUhYMozvj4ByJZuumYNG2abgQRX6C40YWrkCY3mLFNxqSjjr_eyIwuhQt3cb9zD-cgdETJjBLKT-ezMXz2MM5KUpIZoXnEFppS0bQFo7zdRlPCGlFUZVNN0F5Kc0IIr3i9iyaMtoJy0UzR8z2Mqgt9GJxO2EDS0XWQ8CLCuwvL1K_w0r_68OFxtnPajSs8gH5R3qUh4WCxS8E79eUMVt7g6KwaFpnzB2jHqj7B4Wbvo6ery8eLm-Lu4fr24vyu0BVlY0FL2hnbcU6FBmiF0IbxxnLKrDE1EGD5SoQwittSd1SDaBoLoq2J6YgFto9O1n8XMbwtIY1ycElD3ysPOYAsWVXXpMmBM1qtUR1DShGsXEQ3qLiSlMifUuVcrkuVP6VKQvOILDveOCy7Acyf6LfFDJytAcg53x1EmbQDr8G4CHqUJrj_Hb4Bc4aN2A</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Combrink, Monique</creator><creator>Loots, Du Toit</creator><creator>du Preez, Ilse</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5202-9097</orcidid></search><sort><creationdate>20200401</creationdate><title>Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin</title><author>Combrink, Monique ; Loots, Du Toit ; du Preez, Ilse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-121bdfb6618cee988cd367f613fdd5e0e3dfb088da6f2cb1ce877fe8950db0fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antitubercular Agents - metabolism</topic><topic>Antitubercular Agents - toxicity</topic><topic>Biomarkers - metabolism</topic><topic>Biotransformation</topic><topic>Drug-Related Side Effects and Adverse Reactions - diagnosis</topic><topic>Drug-Related Side Effects and Adverse Reactions - etiology</topic><topic>Drug-Related Side Effects and Adverse Reactions - metabolism</topic><topic>Humans</topic><topic>Isoniazid</topic><topic>Isoniazid - metabolism</topic><topic>Isoniazid - toxicity</topic><topic>Metabolomics</topic><topic>Metabolomics - methods</topic><topic>Rifampicin</topic><topic>Rifampin - metabolism</topic><topic>Rifampin - toxicity</topic><topic>Risk Assessment</topic><topic>Toxicity</topic><topic>Toxicity Tests - methods</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Combrink, Monique</creatorcontrib><creatorcontrib>Loots, Du Toit</creatorcontrib><creatorcontrib>du Preez, Ilse</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Toxicology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Combrink, Monique</au><au>Loots, Du Toit</au><au>du Preez, Ilse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin</atitle><jtitle>Toxicology letters</jtitle><addtitle>Toxicol Lett</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>322</volume><spage>104</spage><epage>110</epage><pages>104-110</pages><issn>0378-4274</issn><eissn>1879-3169</eissn><abstract>•Isoniazid and rifampicin are the most important first-line TB drugs.•Despite the drugs’ anti-mycobacterial properties, it can cause severe side effects.•Drug toxicity is a major contributor to TB treatment failure.•Metabolomics can be used to elucidate TB drug toxicity mechanisms.•Metabolomics can contribute to the development of less toxic TB drugs.
Isoniazid and rifampicin are well-known anti-mycobacterial agents and are widely used to treat pulmonary tuberculosis (TB) as part of the combined therapy approach, recommended by the World Health Organization. The ingestion of these first-line TB drugs are, however, not free of side effects, and are toxic to the liver, kidney, and central nervous system. These side effects are associated with poor treatment compliance, resulting in TB treatment failure, relapse and drug resistant TB. This occurrence has subsequently led to the recent application of novel research technologies, towards a better understanding of the underlying toxicity mechanisms of TB drugs in humans, mostly focussing on the 2 most important TB drugs: isoniazid and rifampicin. In this review, we discuss the contribution that one such an approach, termed metabolomics has made toward this field, and also highlight the impact that this might have towards the development of improved TB treatment regimens.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31981687</pmid><doi>10.1016/j.toxlet.2020.01.018</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-5202-9097</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-4274 |
ispartof | Toxicology letters, 2020-04, Vol.322, p.104-110 |
issn | 0378-4274 1879-3169 |
language | eng |
recordid | cdi_proquest_miscellaneous_2345507981 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Animals Antitubercular Agents - metabolism Antitubercular Agents - toxicity Biomarkers - metabolism Biotransformation Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - metabolism Humans Isoniazid Isoniazid - metabolism Isoniazid - toxicity Metabolomics Metabolomics - methods Rifampicin Rifampin - metabolism Rifampin - toxicity Risk Assessment Toxicity Toxicity Tests - methods Tuberculosis |
title | Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T23%3A20%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolomics%20describes%20previously%20unknown%20toxicity%20mechanisms%20of%20isoniazid%20and%20rifampicin&rft.jtitle=Toxicology%20letters&rft.au=Combrink,%20Monique&rft.date=2020-04-01&rft.volume=322&rft.spage=104&rft.epage=110&rft.pages=104-110&rft.issn=0378-4274&rft.eissn=1879-3169&rft_id=info:doi/10.1016/j.toxlet.2020.01.018&rft_dat=%3Cproquest_cross%3E2345507981%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c413t-121bdfb6618cee988cd367f613fdd5e0e3dfb088da6f2cb1ce877fe8950db0fe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2345507981&rft_id=info:pmid/31981687&rfr_iscdi=true |